Who
Katharine Peterson
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Acrivon Therapeutics.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $406
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 May 2024
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $203101 at $2.01 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Sold | $203101 at $2.01 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,227 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,227 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $19099 at $1.92 | filing |
| 14 May 2026filed 18 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $19099 at $1.92 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,900 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,900 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $189116 at $1.63 | filing |
| 14 Feb 2026filed 18 Feb 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $189116 at $1.63 | filing |
| 14 Nov 2025filed 18 Nov 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $22299 at $2.24 | filing |
| 14 Aug 2025filed 18 Aug 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $13899 at $1.39 | filing |
| 14 May 2025filed 16 May 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $11399 at $1.14 | filing |
| 1 Mar 2025filed 4 Mar 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,900 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $629116 at $5.42 | filing |
| 14 Nov 2024filed 18 Nov 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $78499 at $7.92 | filing |
| 14 Aug 2024filed 16 Aug 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $69599 at $7.02 | filing |
| 14 May 2024filed 16 May 2024 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code F | $82899 at $8.36 | filing |
News
No headline names them, or the companies they trade most, lately.